Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors.

Ji C, Roy MD, Golas J, Vitsky A, Ram S, Kumpf SW, Martin M, Barletta F, Meier W, Hooper AT, Sapra P, Khan NK, Finkelstein M, Guffroy M, Buetow BS.

Clin Cancer Res. 2019 May 13. pii: clincanres.4083.2018. doi: 10.1158/1078-0432.CCR-18-4083. [Epub ahead of print]

PMID:
31085720
2.

A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.

Fisher TS, Hooper AT, Lucas J, Clark TH, Rohner AK, Peano B, Elliott MW, Tsaparikos K, Wang H, Golas J, Gavriil M, Haddish-Berhane N, Tchistiakova L, Gerber HP, Root AR, May C.

Cancer Immunol Immunother. 2018 Feb;67(2):247-259. doi: 10.1007/s00262-017-2081-0. Epub 2017 Oct 24.

PMID:
29067496
3.

Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis.

Doherty JR, Yang C, Scott KE, Cameron MD, Fallahi M, Li W, Hall MA, Amelio AL, Mishra JK, Li F, Tortosa M, Genau HM, Rounbehler RJ, Lu Y, Dang CV, Kumar KG, Butler AA, Bannister TD, Hooper AT, Unsal-Kacmaz K, Roush WR, Cleveland JL.

Cancer Res. 2014 Feb 1;74(3):908-20. doi: 10.1158/0008-5472.CAN-13-2034. Epub 2013 Nov 27.

4.

Impaired endothelial progenitor cell mobilization and dysfunctional bone marrow stroma in diabetes mellitus.

Westerweel PE, Teraa M, Rafii S, Jaspers JE, White IA, Hooper AT, Doevendans PA, Verhaar MC.

PLoS One. 2013;8(3):e60357. doi: 10.1371/journal.pone.0060357. Epub 2013 Mar 28.

5.

Investigational antibody drug conjugates for solid tumors.

Sapra P, Hooper AT, O'Donnell CJ, Gerber HP.

Expert Opin Investig Drugs. 2011 Aug;20(8):1131-49. doi: 10.1517/13543784.2011.582866. Epub 2011 May 23. Review.

PMID:
21599617
6.

Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells.

Butler JM, Nolan DJ, Vertes EL, Varnum-Finney B, Kobayashi H, Hooper AT, Seandel M, Shido K, White IA, Kobayashi M, Witte L, May C, Shawber C, Kimura Y, Kitajewski J, Rosenwaks Z, Bernstein ID, Rafii S.

Cell Stem Cell. 2010 Mar 5;6(3):251-64. doi: 10.1016/j.stem.2010.02.001.

7.

Functional heterogeneity of the bone marrow vascular niche.

Kopp HG, Hooper AT, Avecilla ST, Rafii S.

Ann N Y Acad Sci. 2009 Sep;1176:47-54. doi: 10.1111/j.1749-6632.2009.04964.x.

8.

Angiomodulin is a specific marker of vasculature and regulates vascular endothelial growth factor-A-dependent neoangiogenesis.

Hooper AT, Shmelkov SV, Gupta S, Milde T, Bambino K, Gillen K, Goetz M, Chavala S, Baljevic M, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, Vahdat L, Evans T, Rafii S.

Circ Res. 2009 Jul 17;105(2):201-8. doi: 10.1161/CIRCRESAHA.109.196790. Epub 2009 Jun 18.

9.

CEACAM1: a novel urinary marker for bladder cancer detection.

Tilki D, Singer BB, Shariat SF, Behrend A, Fernando M, Irmak S, Buchner A, Hooper AT, Stief CG, Reich O, Ergün S.

Eur Urol. 2010 Apr;57(4):648-54. doi: 10.1016/j.eururo.2009.05.040. Epub 2009 May 28.

PMID:
19487071
10.

Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells.

Hooper AT, Butler JM, Nolan DJ, Kranz A, Iida K, Kobayashi M, Kopp HG, Shido K, Petit I, Yanger K, James D, Witte L, Zhu Z, Wu Y, Pytowski B, Rosenwaks Z, Mittal V, Sato TN, Rafii S.

Cell Stem Cell. 2009 Mar 6;4(3):263-74. doi: 10.1016/j.stem.2009.01.006.

11.

Generation of a functional and durable vascular niche by the adenoviral E4ORF1 gene.

Seandel M, Butler JM, Kobayashi H, Hooper AT, White IA, Zhang F, Vertes EL, Kobayashi M, Zhang Y, Shmelkov SV, Hackett NR, Rabbany S, Boyer JL, Rafii S.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19288-93. doi: 10.1073/pnas.0805980105. Epub 2008 Nov 26.

12.

Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal antibodies.

Patel D, Bassi R, Hooper AT, Sun H, Huber J, Hicklin DJ, Kang X.

Anticancer Res. 2008 Sep-Oct;28(5A):2679-86.

13.

CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors.

Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D'Angelica M, Kemeny N, Lyden D, Rafii S.

J Clin Invest. 2008 Jun;118(6):2111-20. doi: 10.1172/JCI34401.

14.

Does N-cadherin regulate interaction of hematopoietic stem cells with their niches?

Hooper AT, Butler J, Petit I, Rafii S.

Cell Stem Cell. 2007 Aug 16;1(2):127-9. doi: 10.1016/j.stem.2007.07.012.

15.

The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death.

Petit I, Karajannis MA, Vincent L, Young L, Butler J, Hooper AT, Shido K, Steller H, Chaplin DJ, Feldman E, Rafii S.

Blood. 2008 Feb 15;111(4):1951-61. Epub 2007 Nov 16.

16.

Beta-galactosidase staining on bone marrow. The osteoclast pitfall.

Kopp HG, Hooper AT, Shmelkov SV, Rafii S.

Histol Histopathol. 2007 Sep;22(9):971-6. doi: 10.14670/HH-22.971.

PMID:
17523074
17.

In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma.

Mutlu AD, Cavallin LE, Vincent L, Chiozzini C, Eroles P, Duran EM, Asgari Z, Hooper AT, La Perle KM, Hilsher C, Gao SJ, Dittmer DP, Rafii S, Mesri EA.

Cancer Cell. 2007 Mar;11(3):245-58. Erratum in: Cancer Cell. 2007 May;11(5):471.

18.

Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.

Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ, Ellis LM.

Cancer. 2007 Mar 15;109(6):1030-9.

19.

Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization.

Kopp HG, Hooper AT, Broekman MJ, Avecilla ST, Petit I, Luo M, Milde T, Ramos CA, Zhang F, Kopp T, Bornstein P, Jin DK, Marcus AJ, Rafii S.

J Clin Invest. 2006 Dec;116(12):3277-91.

20.

Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma.

Ruan J, Hyjek E, Kermani P, Christos PJ, Hooper AT, Coleman M, Hempstead B, Leonard JP, Chadburn A, Rafii S.

Clin Cancer Res. 2006 Oct 1;12(19):5622-31.

21.

The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma.

Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S, Hicklin DJ.

Int J Cancer. 2006 Oct 1;119(7):1519-29.

22.

Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes.

Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, Heissig B, Hattori K, Zhang F, Hicklin DJ, Wu Y, Zhu Z, Dunn A, Salari H, Werb Z, Hackett NR, Crystal RG, Lyden D, Rafii S.

Nat Med. 2006 May;12(5):557-67. Epub 2006 Apr 30. Erratum in: Nat Med. 2006 Aug;12(8):978.

23.

Autoimmunity and tumor immunity induced by immune responses to mutations in self.

Engelhorn ME, Guevara-Patiño JA, Noffz G, Hooper AT, Lou O, Gold JS, Kappel BJ, Houghton AN.

Nat Med. 2006 Feb;12(2):198-206. Epub 2006 Jan 29.

PMID:
16444264
24.

The bone marrow vascular niche: home of HSC differentiation and mobilization.

Kopp HG, Avecilla ST, Hooper AT, Rafii S.

Physiology (Bethesda). 2005 Oct;20:349-56. Review.

25.

Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells.

Vincent L, Jin DK, Karajannis MA, Shido K, Hooper AT, Rashbaum WK, Pytowski B, Wu Y, Hicklin DJ, Zhu Z, Bohlen P, Niesvizky R, Rafii S.

Cancer Res. 2005 Apr 15;65(8):3185-92.

26.

Tie2 activation contributes to hemangiogenic regeneration after myelosuppression.

Kopp HG, Avecilla ST, Hooper AT, Shmelkov SV, Ramos CA, Zhang F, Rafii S.

Blood. 2005 Jul 15;106(2):505-13. Epub 2005 Apr 7.

27.
28.

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL.

Cancer Res. 2003 Dec 15;63(24):8912-21.

29.

Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis.

Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen P, Hicklin DJ.

J Exp Med. 2002 Jun 17;195(12):1575-84. Erratum in: J Exp Med 2002 Aug 19;196(4):557.

30.
31.

Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice.

Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ.

Cancer. 2000 Jul 1;89(1):74-82.

PMID:
10897003

Supplemental Content

Loading ...
Support Center